Table 1: Overview of protein expression studies using osteosarcoma samples published so far.

Sample typeSample entity (cases)Purpose of studyMethodLiteratureStudy contents

Osteosarcoma (16)Chemosensitivity2D-DIGEKawai et al. Chemosensitivity (poor responder (7) versus good responder (9))
Patient's tissue samples (osteosarcoma, normal bone, and benign tumor)Osteosarcoma (5) and normal bone (5)Tumor-specific and malignancy2D-DIGEFolio et al.Tumor-specific proteins (osteosarcoma (5) versus normal bone (5))
Osteosarcoma (12)Chemosensitivity2D-DIGEKikuta et al.Chemosensitivity (poor responder (6) versus good responder (6))
Osteosarcoma (5), chondroblastoma (2), osteoblastoma (2), and giant cell tumor (1)Tumor-specific and malignancy2DELi et al.Tumor-specific proteins (osteosarcoma (5) versus chondroblastoma (2), osteoblastoma (2), and giant cell tumor (1))

Patient's plasma samples (osteosarcoma and benign tumor)Osteosarcoma (29) and osteoblastoma (20)Tumor-specific and malignancySELDILi et al. Tumor-specific proteins (osteosarcoma (29) versus osteoblastoma (20))
Osteosarcoma (54)ChemosensitivitySELDILi et al.Tumor-specific proteins (poor responder (27) versus good responder (27))

Osteosarcoma cell (1), osteoblastic cell (1)Tumor-specific and malignancy2DESpreafico et al. Tumor-specific proteins (SaOS-2 (1) versus osteoblastic cell (1))
Cell line samples (osteosarcoma cell line versus normal bone or osteoblast cell)Osteosarcoma cell (3), osteoblastic cell (1)Tumor-specific and malignancy2DEGuo et al.Tumor-specific proteins (U2OS (1), IOR/OS9 (1) and SaOS-2 (1) versus osteoblastic cell (1))
Osteosarcoma cell (1), osteoblastic cell (1)Tumor-specific and malignancy2DELiu et al.Tumor-specific proteins (SaOS-2 (1) versus osteoblastic cell (1))
Osteosarcoma cell (1), osteoblastic cell (1)Tumor-specific and malignancyiTRAQZhang et al.Tumor-specific proteins of plasma membrane (MG63 (1) versus osteoblastic cell (1))
Osteosarcoma cell (1), osteoblastic cell (1)Tumor-specific and malignancy 2D-DIGEHua et al.Tumor-specific proteins of plasma membrane (MG63 (1) versus osteoblastic cell (1))

Cell line sample (osetosarcoma cell)Osteosarcoma cell (1)Tumor specific2D-DIGENiforou et al.Characteristic proteins of U2OS cell line

Cell line sample (high metastatic osetosarcoma cell versus low metastatic osteosarcoma cell)Osteosarcoma cell (2)MetastasisMALDI and 2D-DIGECates et al.Proteins corresponding to metastasis (high metastatic osetosarcoma cell (1) versus low metastatic osetosarcoma cell (2))

Osteosarcoma cell (2)Drug-sensitivity2DEKang et al. Drug-sensitivity: Ascochlorin (drug-treatment U2OS (1) versus no-treatment U2OS (1))
Cell line sample (drug treatment cell versus nontreatment cell)Osteosarcoma cell (2)Drug-sensitivity2DEChang et al.Drug-sensitivity: Ascochlorin (drug-treatment USOS (1) versus no-treatment USOS (1))
Osteosarcoma cell (2)Drug-sensitivity2DEZhang et al.Drug-sensitivity: DATS (drug-treatment SaOS2 (1) versus non-treatment SaOS2 (1))

Cell line sample (target inhibition or activation cell versus non-treatment cell)Osteosarcoma cell (2)Target related proteins2D-DIGELi et al. Target-related proteins: E2F1 (E2F1-activated SaOS2 (1) versus non-treatment SaOS2 (1))
Osteosarcoma cell (4)Target related proteins2D-DIGEAnnunen-
Rasia et al.
Target-related proteins: (i) OXPHOS, (ii) CI or CV, and (iii) mtDNA (inhibited SaOS2 (1) versus non-treatment SaOS2 (1))

2D-DIGE: 2-dimensional fluorescence difference gel electrophoresis, 2DE: 2-dimensional electrophoresis, MALDI: matrix-assisted laser desorption/ionization, and SELDI: surface-enhanced laser desorption/ionization.